Intervention1: JNJ-77242113 (Icotrokinra) dose 1: Participants will receive icotrokinra Dose 1 once daily up to Week 52. Participants who continue into a long term extension (LTE till 104 weeks) will
Sponsors
Johnson and Johnson Private Limited
Conditions
Health Condition 1: L405- Arthropathic psoriasis
Phase 3
A Study of the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-na ve Participants with Active Psoriatic Arthritis
Active, not recruitingCTRI/2025/04/084370
Target: 540Updated: 2026-02-02
A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-experienced Participants with Active Psoriatic Arthritis
RecruitingCTRI/2025/04/084956
Target: 750Updated: 2025-08-18